Bruker

On valuation, the picture is expensive. The owner-earnings multiple stands at 65.6×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 22% a year, against analyst forecasts of 15%. The gap between price and consensus is worth watching: demanding expectations.

Growth is moderate; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.